News Conference News VIVA 2022 TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years L.A. McKeown November 03, 2022
News Daily News LEVANT 2: DCB Beats Standard Balloon Angioplasty at 1 Year in Femoropopliteal Disease Yael L. Maxwell June 26, 2015
News Industry News The New England Journal of Medicine publishes LEVANT 2 results for the Lutonix® Drug Coated Balloon, showing superior efficacy compared to standard PTA June 25, 2015
News Conference News TCT 2013 LEVANT 2, RIBS Show Promise for Paclitaxel-Coated Balloons in PAD and CAD October 30, 2013